Compare Akamai Technologies, Inc. (AKAM) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Akamai Technologies, Inc. vs Summit Therapeutics Inc — how do they compare? Akamai Technologies, Inc. trades at $123.41 (market cap $16.63B), while Summit Therapeutics Inc trades at $15.69 (market cap $12.32B). The key difference: Akamai Technologies, Inc. is the larger of the two by market cap, and Akamai Technologies, Inc. is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| AKAM | SMMT | |
|---|---|---|
Market Cap | $16.63B | $12.32B |
Sector | Technology | Health |
52-Week High | $161.14 | $29.32 |
52-Week Low | $70.53 | $13.05 |
Enterprise Value | $21.56B | $11.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Akamai Technologies (AKAM) trades at $114.37, up 1.06% on the day but down significantly from its 26-year high of $165.45 in May 2026. The stock faces a bearish technical signal despite recent earnings beats. Revenue growth has slowed to 5% annually, with net income margin declining from 14.47% in 2022 to 10.74% in 2025. The company continues strategic moves in cybersecurity, completing the LayerX acquisition and expanding its NVIDIA partnership for AI security.
While analyst consensus remains positive with a $170.20 price target, near-term headwinds include declining profitability, high valuation multiples, and competitive pressures. The stock's current pullback presents a potential entry point for long-term investors believing in its cybersecurity and cloud computing positioning, though execution risks and margin compression require monitoring.
Summit Therapeutics (SMMT) trades at $15.93, up 3.31% today, with a bullish technical signal despite mixed moving averages and overbought RSI readings. The company reported a net loss of -$1.08B in 2025 and negative ROE/ROA, but recent Phase III trial success for ivonescimab in lung cancer has driven optimism. Cash flow remains volatile, with 2025 net cash flow positive at $120.4M but turning negative in 2026 projections.
Outlook hinges on ivonescimab's regulatory approval and commercial potential, with a consensus price target of $22.93 implying 44% upside. High volatility and binary clinical outcomes pose significant risks, but strong analyst buy ratings (66.7%) reflect confidence in the drug's prospects. Investors face substantial dilution risk from a proposed $500M stock offering announced June 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Akamai Technologies, Inc.
Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.
Read more on AKAM →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
